\-\ Texto\\:\\ \ \(0\)\
\-\ supraclavicular\\ vascular\\ mass\\ with\\ prominent\\ superficial\\ veins\\.\ \(0\)\
\-\ this\\ patient\\ was\\ treated\\ with\\ a\\ short\\ course\\ of\\ propranolol\\ with\\ marked\\ interval\\ decrease\\ in\\ the\\ size\\ of\\ the\\ lesion\\.\ \(0\)\
\-\ lobulated\\,\\ intensely\\ enhancing\\ mass\\ lesion\\ with\\ high\\ flow\\ intralesional\\ vessels\\.\ \(0\)\
\-\ capillary\\ hemangioma\ \(2\)\
\-\ \\â\\€\\¢\\ capillary\\ \\(infantile\\)\\ hemangioma\ \(0\)\
\-\ \\â\\€\\¢\\ venous\\ malformation\ \(0\)\
\-\ \\â\\€\\¢\\ sarcoma\\ \\(rhabdomyosarcoma\\,\\ extraosseous\\ ewings\\,\\ undifferentiated\\ sarcoma\\)\ \(0\)\
\-\ \\â\\€\\¢\\ plexiform\\ neurofibroma\ \(0\)\
\-\ \\â\\€\\¢\\ arteriovenous\\ malformation\ \(0\)\
\-\ 15\\ month\\ old\\ baby\\ girl\\ with\\ enlarging\\ right\\ supraclavicular\\ \\/\\ shoulder\\ mass\\.\ \(1\)\
\-\ infantile\\ hemangiomas\\ are\\ benign\\ neoplasms\\ of\\ endothelial\\ cells\\.\\ \\ they\\ are\\ the\\ most\\ common\\ childhood\\ tumor\\,\\ occurring\\ in\\ 12\\%\\ of\\ children\\.\\ \\ they\\ are\\ more\\ common\\ in\\ females\\,\\ whites\\,\\ premature\\ infants\\,\\ and\\ twins\\.\\ \\ \ \(0\)\
\-\ at\\ birth\\ these\\ lesions\\ can\\ be\\ small\\ and\\ inconspicuous\\,\\ with\\ 60\\%\\ absent\\ at\\ birth\\.\\ \\ the\\ natural\\ history\\ is\\ a\\ two\\ stage\\ process\\ of\\ proliferation\\ and\\ regression\\.\\ \\ the\\ typical\\ hemangioma\\ will\\ begin\\ to\\ involute\\ by\\ 10\\ months\\ of\\ age\\,\\ with\\ half\\ of\\ all\\ lesions\\ having\\ resolved\\ by\\ 5\\ years\\.\ \(0\)\
\-\ clinically\\,\\ hemangiomas\\ appear\\ as\\ erythematous\\ or\\ blanching\\ macules\\,\\ or\\ appear\\ as\\ a\\ small\\ telangiectasia\\.\\ \\ the\\ clinical\\ appearance\\ depends\\ upon\\ the\\ degree\\ of\\ dermal\\ involvement\\ and\\ lesion\\ depth\\.\\ \\ lesions\\ involving\\ the\\ skin\\ have\\ a\\ more\\ characteristic\\ strawberry\\ appearance\\.\\ \\ deeper\\ lesions\\ demonstrate\\ a\\ blue\\ appearance\\.\\ \\ \ \(0\)\
\-\ most\\ hemangiomas\\ are\\ generally\\ treated\\ conservatively\\.\\ corticosteroids\\ are\\ the\\ first\\ line\\ of\\ treatment\\ for\\ problematic\\ infantile\\ capillary\\ hemangiomas\\.\\ \\ other\\ options\\ include\\ interferon\\ alpha\\ and\\ vincristine\\.\\ \\ propranolol\\ has\\ also\\ been\\ observed\\ to\\ inhibit\\ growth\\.\\ while\\ the\\ mechanism\\ of\\ action\\ is\\ unclear\\,\\ potential\\ explanations\\ include\\ vasoconstriction\\;\\ down\\-regulation\\ of\\ the\\ raf\\-mitogen\\-activated\\ protein\\ kinase\\ pathway\\;\\ and\\ the\\ triggering\\ of\\ apoptosis\\ of\\ capillary\\ endothelial\\ cells\\.\\ \ \(0\)\
\-\ capillary\\ hemangiomas\\ can\\ develop\\ life\\ threatening\\ complications\\,\\ such\\ as\\ consumptive\\ coagulopathy\\,\\ compression\\ of\\ vital\\ structures\\,\\ and\\ bleeding\\ secondary\\ to\\ fissure\\ or\\ ulcer\\ formation\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hemangiomas\\:\\ 0\\.31900200561698916\ \(0\)\
\-\ capillary\\:\\ 0\\.30645503831799475\ \(0\)\
\-\ infantile\\:\\ 0\\.20023647105931003\ \(0\)\
\-\ propranolol\\:\\ 0\\.18678003897488046\ \(0\)\
\-\ of\\:\\ 0\\.15999334436811632\ \(0\)\
\-\ hemangioma\\:\\ 0\\.147367658870087\ \(0\)\
\-\ endothelial\\:\\ 0\\.14693828607651016\ \(0\)\
\-\ the\\:\\ 0\\.13982856370459076\ \(0\)\
\-\ lesions\\:\\ 0\\.13415296131142793\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.12760080224679565\ \(0\)\
\-\ are\\:\\ 0\\.11079562535045943\ \(0\)\
\-\ appearance\\:\\ 0\\.10561643317411011\ \(0\)\
\-\ birth\\:\\ 0\\.10436252988836602\ \(0\)\
\-\ sarcoma\\:\\ 0\\.09797569925316728\ \(0\)\
\-\ consumptive\\:\\ 0\\.09339001948744023\ \(0\)\
\-\ appear\\:\\ 0\\.09198540024817893\ \(0\)\
\-\ malformation\\:\\ 0\\.09007941006934084\ \(0\)\
\-\ cells\\:\\ 0\\.0899886134204475\ \(0\)\
\-\ strawberry\\:\\ 0\\.08923914935245507\ \(0\)\
\-\ explanations\\:\\ 0\\.08923914935245507\ \(0\)\
\-\ inhibit\\:\\ 0\\.08629406012274954\ \(0\)\
\-\ triggering\\:\\ 0\\.08629406012274954\ \(0\)\
\-\ and\\:\\ 0\\.08446963102478063\ \(0\)\
\-\ extraosseous\\:\\ 0\\.08400967144307654\ \(0\)\
\-\ inconspicuous\\:\\ 0\\.08400967144307654\ \(0\)\
\-\ involute\\:\\ 0\\.08400967144307654\ \(0\)\
\-\ problematic\\:\\ 0\\.08400967144307654\ \(0\)\
\-\ apoptosis\\:\\ 0\\.08400967144307654\ \(0\)\
\-\ lesion\\:\\ 0\\.0839909153918369\ \(0\)\
\-\ they\\:\\ 0\\.08345193191793149\ \(0\)\
\-\ blanching\\:\\ 0\\.08214318998776438\ \(0\)\
\-\ deeper\\:\\ 0\\.08056510240294577\ \(0\)\
\-\ vasoconstriction\\:\\ 0\\.08056510240294577\ \(0\)\
\-\ with\\:\\ 0\\.08004447017662598\ \(0\)\
\-\ interferon\\:\\ 0\\.0779923198527792\ \(0\)\
\-\ plexiform\\:\\ 0\\.07691371207838585\ \(0\)\
\-\ twins\\:\\ 0\\.07691371207838585\ \(0\)\
\-\ macules\\:\\ 0\\.07691371207838585\ \(0\)\
\-\ kinase\\:\\ 0\\.07691371207838585\ \(0\)\
\-\ whites\\:\\ 0\\.07593799266135454\ \(0\)\
\-\ intralesional\\:\\ 0\\.07422780898071427\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.07422780898071427\ \(0\)\
\-\ depth\\:\\ 0\\.07422780898071427\ \(0\)\
\-\ pathway\\:\\ 0\\.07422780898071427\ \(0\)\
\-\ treated\\:\\ 0\\.07273131617032225\ \(0\)\
\-\ threatening\\:\\ 0\\.07210214139336817\ \(0\)\
\-\ coagulopathy\\:\\ 0\\.07210214139336817\ \(0\)\
\-\ ewings\\:\\ 0\\.07148150862593537\ \(0\)\
\-\ as\\:\\ 0\\.0703808216863517\ \(0\)\
\-\ intensely\\:\\ 0\\.06981775271369516\ \(0\)\
\-\ action\\:\\ 0\\.06981775271369516\ \(0\)\
\-\ include\\:\\ 0\\.0694917412488272\ \(0\)\
\-\ vincristine\\:\\ 0\\.06884203329666384\ \(0\)\
\-\ telangiectasia\\:\\ 0\\.06838696702828964\ \(0\)\
\-\ dermal\\:\\ 0\\.06838696702828964\ \(0\)\
\-\ natural\\:\\ 0\\.06795127125838299\ \(0\)\
\-\ depends\\:\\ 0\\.06795127125838299\ \(0\)\
\-\ begin\\:\\ 0\\.06753336403402214\ \(0\)\
\-\ mass\\:\\ 0\\.06691864596467303\ \(0\)\
\-\ regression\\:\\ 0\\.06637318367356439\ \(0\)\
\-\ blue\\:\\ 0\\.06637318367356439\ \(0\)\
\-\ common\\:\\ 0\\.06623593274014156\ \(0\)\
\-\ unclear\\:\\ 0\\.06566688257870998\ \(0\)\
\-\ more\\:\\ 0\\.06413274369373385\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.06324689846789298\ \(0\)\
\-\ proliferation\\:\\ 0\\.06272179334900446\ \(0\)\
\-\ alpha\\:\\ 0\\.06151601244372481\ \(0\)\
\-\ can\\:\\ 0\\.06129012152443418\ \(0\)\
\-\ or\\:\\ 0\\.06094615791559148\ \(0\)\
\-\ infants\\:\\ 0\\.0608553118936923\ \(0\)\
\-\ most\\:\\ 0\\.060783461946126896\ \(0\)\
\-\ small\\:\\ 0\\.06024660342947583\ \(0\)\
\-\ erythematous\\:\\ 0\\.0592772243088737\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.05909602833290782\ \(0\)\
\-\ childhood\\:\\ 0\\.05909602833290782\ \(0\)\
\-\ occurring\\:\\ 0\\.058917983751575344\ \(0\)\
\-\ females\\:\\ 0\\.058742982816879175\ \(0\)\
\-\ conservatively\\:\\ 0\\.058742982816879175\ \(0\)\
\-\ ulcer\\:\\ 0\\.057910222663986786\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.057751501571659876\ \(0\)\
\-\ premature\\:\\ 0\\.05759520379698797\ \(0\)\
\-\ fissure\\:\\ 0\\.05699283562920069\ \(0\)\
\-\ superficial\\:\\ 0\\.05642395009268606\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.05601711621216937\ \(0\)\
\-\ half\\:\\ 0\\.055005201216880975\ \(0\)\
\-\ mechanism\\:\\ 0\\.055005201216880975\ \(0\)\
\-\ enlarging\\:\\ 0\\.05453443756942434\ \(0\)\
\-\ neoplasms\\:\\ 0\\.05442005307903412\ \(0\)\
\-\ protein\\:\\ 0\\.054195048298908255\ \(0\)\
\-\ lobulated\\:\\ 0\\.05386655042352929\ \(0\)\
\-\ develop\\:\\ 0\\.053759352529001624\ \(0\)\
\-\ interval\\:\\ 0\\.05284196549421551\ \(0\)\
\-\ baby\\:\\ 0\\.052648803058224586\ \(0\)\
\-\ options\\:\\ 0\\.052648803058224586\ \(0\)\
\-\ resolved\\:\\ 0\\.05245921791077736\ \(0\)\
\-\ potential\\:\\ 0\\.05218126494418301\ \(0\)\
\-\ observed\\:\\ 0\\.05200006896821713\ \(0\)\
\-\ vital\\:\\ 0\\.05200006896821713\ \(0\)\
\-\ veins\\:\\ 0\\.05182202438688465\ \(0\)\
\-\ degree\\:\\ 0\\.051057056624967755\ \(0\)\
\-\ having\\:\\ 0\\.050345297089362445\ \(0\)\
\-\ short\\:\\ 0\\.0501936305318633\ \(0\)\
\-\ decrease\\:\\ 0\\.0501936305318633\ \(0\)\
\-\ by\\:\\ 0\\.04959777350710218\ \(0\)\
\-\ generally\\:\\ 0\\.04946727594306315\ \(0\)\
\-\ clinically\\:\\ 0\\.04852987461962308\ \(0\)\
\-\ growth\\:\\ 0\\.048152998734301615\ \(0\)\
\-\ absent\\:\\ 0\\.04790924185219028\ \(0\)\
\-\ life\\:\\ 0\\.04790924185219028\ \(0\)\
\-\ children\\:\\ 0\\.04784919883323195\ \(0\)\
\-\ bleeding\\:\\ 0\\.04773015905723836\ \(0\)\
\-\ characteristic\\:\\ 0\\.047210973166838414\ \(0\)\
\-\ stage\\:\\ 0\\.046504672071984006\ \(0\)\
\-\ formation\\:\\ 0\\.04629680086135673\ \(0\)\
\-\ prominent\\:\\ 0\\.045992700124089465\ \(0\)\
\-\ upon\\:\\ 0\\.045942883454565236\ \(0\)\
\-\ line\\:\\ 0\\.04550511724165715\ \(0\)\
\-\ shoulder\\:\\ 0\\.045363258546086666\ \(0\)\
\-\ vessels\\:\\ 0\\.04531640580807799\ \(0\)\
\-\ typical\\:\\ 0\\.04513111015427677\ \(0\)\
\-\ complications\\:\\ 0\\.04472606502219397\ \(0\)\
\-\ marked\\:\\ 0\\.04416791854470622\ \(0\)\
\-\ at\\:\\ 0\\.04411481017629214\ \(0\)\
\-\ structures\\:\\ 0\\.04387952467421267\ \(0\)\
\-\ process\\:\\ 0\\.04379859693746886\ \(0\)\
\-\ to\\:\\ 0\\.04379764196556358\ \(0\)\
\-\ 60\\:\\ 0\\.043678392362080945\ \(0\)\
\-\ in\\:\\ 0\\.04358207006251711\ \(0\)\
\-\ skin\\:\\ 0\\.0434421363680724\ \(0\)\
\-\ course\\:\\ 0\\.04313537767531003\ \(0\)\
\-\ compression\\:\\ 0\\.04276442022877282\ \(0\)\
\-\ involvement\\:\\ 0\\.04226667540782478\ \(0\)\
\-\ venous\\:\\ 0\\.04169310138696634\ \(0\)\
\-\ girl\\:\\ 0\\.040964949044998734\ \(0\)\
\-\ involving\\:\\ 0\\.040904012523496895\ \(0\)\
\-\ benign\\:\\ 0\\.04011501380214773\ \(0\)\
\-\ 12\\:\\ 0\\.03992001161318468\ \(0\)\
\-\ size\\:\\ 0\\.039540808803114974\ \(0\)\
\-\ 15\\:\\ 0\\.039461346784089454\ \(0\)\
\-\ first\\:\\ 0\\.03940871270729333\ \(0\)\
\-\ flow\\:\\ 0\\.03889674075939877\ \(0\)\
\-\ vascular\\:\\ 0\\.03855300996829777\ \(0\)\
\-\ while\\:\\ 0\\.03774102012690778\ \(0\)\
\-\ will\\:\\ 0\\.03758607416860992\ \(0\)\
\-\ such\\:\\ 0\\.037564129239765494\ \(0\)\
\-\ clinical\\:\\ 0\\.03700947289007048\ \(0\)\
\-\ age\\:\\ 0\\.03666241235251442\ \(0\)\
\-\ enhancing\\:\\ 0\\.03658243299739025\ \(0\)\
\-\ years\\:\\ 0\\.035796772548646494\ \(0\)\
\-\ month\\:\\ 0\\.03552376155916274\ \(0\)\
\-\ all\\:\\ 0\\.03476253019747304\ \(0\)\
\-\ two\\:\\ 0\\.03467950212365915\ \(0\)\
\-\ secondary\\:\\ 0\\.03461356112023919\ \(0\)\
\-\ 10\\:\\ 0\\.034147783758167405\ \(0\)\
\-\ been\\:\\ 0\\.03402293702324289\ \(0\)\
\-\ months\\:\\ 0\\.03399196179420813\ \(0\)\
\-\ high\\:\\ 0\\.03318920747445131\ \(0\)\
\-\ these\\:\\ 0\\.03297695442451598\ \(0\)\
\-\ is\\:\\ 0\\.03198500281600307\ \(0\)\
\-\ tumor\\:\\ 0\\.030545183819904207\ \(0\)\
\-\ demonstrate\\:\\ 0\\.03035914535811641\ \(0\)\
\-\ other\\:\\ 0\\.030326663135035195\ \(0\)\
\-\ have\\:\\ 0\\.029172661923934067\ \(0\)\
\-\ treatment\\:\\ 0\\.02781773969683304\ \(0\)\
\-\ also\\:\\ 0\\.027468423252395718\ \(0\)\
\-\ has\\:\\ 0\\.02667419184269159\ \(0\)\
\-\ be\\:\\ 0\\.023689456014221778\ \(0\)\
\-\ history\\:\\ 0\\.02231115491411952\ \(0\)\
\-\ was\\:\\ 0\\.0203520423661001\ \(0\)\
\-\ this\\:\\ 0\\.02006636901259991\ \(0\)\
\-\ right\\:\\ 0\\.019361126091852164\ \(0\)\
\-\ patient\\:\\ 0\\.0189937148908232\ \(0\)\
\-\ for\\:\\ 0\\.017699777933248485\ \(0\)\
\-\ old\\:\\ 0\\.017283256349988115\ \(0\)\
